Sasaki Atsushi, Kunimoto Masaru, Takeno Sachio, Sumiya Takahiro, Ishino Takashi, Sugino Hirotoshi, Hirakawa Katsuhiro
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Hiroshima University, Hiroshima, Japan.
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Hiroshima University, Hiroshima, Japan; Kunimoto ENT Clinic, Hiroshima, Japan.
Auris Nasus Larynx. 2018 Aug;45(4):718-721. doi: 10.1016/j.anl.2017.10.006. Epub 2017 Nov 1.
This study investigated: (i) changes in the incidence of acute otitis media (AOM) following introduction of public funding for free inoculation with 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) and (ii) changes in the rate of myringotomies for AOM (MyfA) in children 1year following the publication of the first edition of the clinical practice guidelines for the diagnosis and management of AOM in children in Japan.
PCV7 was launched on the Japanese market in 2010 and gained public funding in 2011. PCV7 was replaced with PCV13 in November 2013. Using the Japan Medical Data Center Claims Database, an 11-year study conducted between January 2005 and December 2015 investigated the decline in the incidence of visits to medical institutions (VtMI) due to all-cause AOM in children <15years. The rate of MyfA from January 2007 to December 2015was also investigated and changes before and after introduction of public funding for PCV7 (pfPCV7) and PCV13 (pfPCV13) for children were examined. Statistical data for the age group between 10 years and <15years served as the control. An analysis was conducted to examine changes for each age group, from infants that had received PCVs to children <5years. Statistical analysis was performed using the chi-square test and Ryan's multiple comparison tests. Ryan's multiple comparison tests were applied at a 5% level of significance. Due to significant changes in the guidelines on the indications for myringotomy introduced in 2013, statistical analysis of the rate of MyfA was limited to the pre- and post-PCV7 period.
After introduction of pfPCV7 and pfPCV13, no significant suppression of the incidence of VtMI was observed in any age group. There was a gradual decline in the rate of MyfA after 2011. Compared to the control group, significant differences in all age groups from infants to children <5years were observed (p<0.009, chi-square test). Within 2 years after the introduction of PCV7, a significant decline in the rate of MyfA was observed in 1- and 5-year-olds using Ryan's multiple comparison tests at a 5% level of significance.
The preventative effect of PCVs on AOM was not established in this study. There was, however, a significant decline in the rate of MyfA among 1- and 5-year-olds. Taking into consideration past studies, PCV7 may play a role in preventing the aggravation of AOM in 1-year-olds. When evaluating the effectiveness of PCVs, measures to evaluate severity may be as important as evaluating disease prevention.
本研究调查了:(i)在为免费接种7价和13价肺炎球菌结合疫苗(分别为PCV7和PCV13)引入公共资金后急性中耳炎(AOM)发病率的变化,以及(ii)在日本儿童AOM诊断和管理临床实践指南第一版发布后1年内儿童AOM鼓膜切开术(MyfA)发生率的变化。
PCV7于2010年在日本市场推出,并于2011年获得公共资金。2013年11月PCV7被PCV13取代。利用日本医疗数据中心索赔数据库,在2005年1月至2015年12月期间进行的一项为期11年的研究调查了15岁以下儿童因各种原因导致的AOM就诊医疗机构(VtMI)发病率的下降情况。还调查了2007年1月至2015年12月期间的MyfA发生率,并检查了为儿童引入PCV7(pfPCV7)和PCV13(pfPCV13)公共资金前后的变化。10岁至15岁年龄组的统计数据用作对照。对每个年龄组(从接种过PCV的婴儿到5岁以下儿童)的变化进行了分析。使用卡方检验和瑞安多重比较检验进行统计分析。瑞安多重比较检验在5%的显著性水平上应用。由于2013年引入的鼓膜切开术适应症指南发生了重大变化,MyfA发生率的统计分析仅限于PCV7之前和之后的时期。
在引入pfPCV7和pfPCV13后,在任何年龄组中均未观察到VtMI发病率的显著抑制。2011年后MyfA发生率逐渐下降。与对照组相比,在从婴儿到5岁以下儿童的所有年龄组中均观察到显著差异(卡方检验,p<0.009)。在引入PCV7后的2年内,使用瑞安多重比较检验在5%的显著性水平上观察到1岁和5岁儿童的MyfA发生率显著下降。
本研究未证实PCV对AOM的预防作用。然而,1岁和5岁儿童的MyfA发生率显著下降。考虑到以往的研究,PCV7可能在预防1岁儿童AOM病情加重方面发挥作用。在评估PCV的有效性时,评估严重程度的措施可能与评估疾病预防同样重要。